Patents by Inventor James E. Dowling

James E. Dowling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibiting (?-v)(?-6) integrin
    Patent number: 11739087
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: August 29, 2023
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Kristopher N. Hahn, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20230242524
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: October 17, 2022
    Publication date: August 3, 2023
    Inventors: Bryce A. Harrison, James E. Dowling, Aleksey I. Gerasyuto, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Cheng Zhong, Fu-Yang Lin, Brian Sosa, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20230219949
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: October 19, 2022
    Publication date: July 13, 2023
    Inventors: Bryce A. Harrison, James E. Dowling, Aleksey I. Gerasyuto, Matthew M. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Tyler Day, Byungchan Kim, Kyle D. Konze
  • INHIBITORS OF AV ß6 INTEGRIN
    Publication number: 20230219947
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: October 17, 2022
    Publication date: July 13, 2023
    Inventors: Bryce A. Harrison, James E. Dowling, Aleksey I. Gerasyuto, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • Inhibiting human integrin (alpha-4) (beta-7)
    Patent number: 11370773
    Abstract: Disclosed are small molecule antagonists of human ?4?7 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: June 28, 2022
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Matthew G. Bursavich, Dan Cui, James E. Dowling, Kristopher N. Hahn, Bryce A. Harrison, Fu-Yang Lin, Blaise S. Lippa, Bruce N. Rogers, Dawn M. Troast, Cheng Zhong, Kyle D. Konze, Aleksey I. Gerasyuto, Byungchan Kim, Salma Rafi, Tyler Day, Eugene Hickey, Evelyne Houang, Robert Zahler
  • INHIBITING (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20220073511
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: April 23, 2021
    Publication date: March 10, 2022
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Kristopher N. Hahn, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • Inhibiting human integrin (?-4) (?-7)
    Patent number: 11104661
    Abstract: Disclosed are small molecule antagonists of human ?4?7 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: August 31, 2021
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Matthew G. Bursavich, Dan Cui, James E. Dowling, Kristopher N. Hahn, Bryce A. Harrison, Fu-Yang Lin, Blaise S. Lippa, Bruce N. Rogers, Dawn M. Troast, Cheng Zhong, Kyle D. Konze, Aleksey I. Gerasyuto, Byungchan Kim, Salma Rafi, Tyler Day, Eugene Hickey, Evelyne Houang, Robert Zahler
  • Inhibiting (?-V)(?-6) integrin
    Patent number: 11021480
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: June 1, 2021
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato
  • INHIBITING (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20200354359
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: July 27, 2020
    Publication date: November 12, 2020
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Kristopher N. Hahn, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • INHIBITING (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20200071322
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Kristopher N. Hahn, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • Triazolopyrazines and methods of making and using the same
    Patent number: 7674791
    Abstract: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: March 9, 2010
    Assignee: Biogen IDEC MA Inc.
    Inventors: James E. Dowling, Gang Yao, Hexi Chang, Hairuo Peng, Jeffrey Vessels, Russell C. Petter, Gnanasambandam Kumaravel
  • ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20090221821
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Application
    Filed: February 10, 2009
    Publication date: September 3, 2009
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Carol L. Ensinger, James E. Dowling, Russell C. Petter, Gnanasambandam Kumaravel
  • Adenosine receptor antagonists and methods of making and using the same
    Patent number: 7579354
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: August 25, 2009
    Inventors: William F. Kiesman, Carol L. Ensinger, Russell C. Petter, James E. Dowling, Gnanasambandam Kumaravel, He Xi Chang, Ko Chung Lin
  • Adenosine receptor antagonists and methods of making and using the same
    Publication number: 20040067966
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Application
    Filed: August 21, 2003
    Publication date: April 8, 2004
    Applicant: Biogen, Inc.
    Inventors: William F. Kiesman, Carol L. Ensinger, Russell C. Petter, James E. Dowling, Gnanasambandam Kumaravel, He Xi Chang, Ko Chung Lin
  • Adenosine receptor antagonists and methods of making and using the same
    Publication number: 20030225038
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Application
    Filed: June 12, 2003
    Publication date: December 4, 2003
    Applicant: Biogen, Inc.
    Inventors: Carol L. Ensinger, James E. Dowling, Russell C. Petter, Gnanasambandam Kumaravel
  • Adenosine receptor antagonists and methods of making and using the same
    Patent number: 6649600
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be usefull in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I: wherein: R3 is an optionally substituted bicyclic, tricylic, or pentacyclic group selected from:  and wherein R1, R2, R6, X1, X2, and Z are as described in the specification.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: November 18, 2003
    Assignee: Biogen, Inc.
    Inventors: William F. Kiesman, Carol L. Ensinger, Russell C. Petter, James E. Dowling, Gnanasambandam Kumaravel, He Xi Chang, Ko Chung Lin
  • Adenosine receptor antagonists and methods of making and using the same
    Patent number: 6605600
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I: R3 is an optionally substituted group selected from: and wherein X1, X2, Z, R1, R2, and R6 are as described in the specification.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: August 12, 2003
    Assignee: Biogen, Incorporated
    Inventors: Carol L. Ensinger, James E. Dowling, Russell C. Petter, Gnanasambandam Kumaravel